Birmingham Atrial Fibrillation Treatment of the Aged "BAFTA"

Completed

Phase N/A Results

Trial Description

To determine whether patients aged 75 years and older with non-rheumatic atrial fibrillation should be treated with aspirin or warfarin.

Interventions

  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Warfarin (Coumadin®)Drug
    Other Names: Coumadin; Acenocoumarol
    Intervention Desc: Anticoagulant (Vitamin K antagonist)

Trial Design

Primary care based randomized, controlled trial.

Patient Involvement

Eligible patients with atrial fibrillation are randomised to adjusted dose warfarin (target INR 2.5, range 2-3) or aspirin (75mg). Patients are followed up after the first 3 months, then every 6 months for an average of 3 years.

Outcomes

Type Measure Time Frame Safety Issue
Primary Fatal or non-fatal disabling stroke (ischemic or hemorrhagic), other intra-cranial hemorrhage, or significant arterial embolism.
Secondary Major extra-cranial hemorrhage, death (all cause, vascular), hospital admissions (all cause, vascular), cognition, quality of life, disability and compliance with study medication.

Sponsors

Medical Research Council